Posted by Michael Wonder on 07 Aug 2024
Durvalumab in combination with chemotherapy before surgery (neo-adjuvant) then alone after surgery (adjuvant) for the treatment of adults with resectable non-small-cell lung cancer
30 July 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use of durvalumab as neo-adjuvant and adjuvant (as monotherapy) treatment in the NHS in England.
For the time being, durvalumab is not recommended as neo-adjuvant treatment with platinum-based chemotherapy, then alone as adjuvant treatment, for adults with non-small-cell lung cancer whose cancer:
- Is resectable (tumours 4 cm or over, or node positive) and
- Has no epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements
